低リスク膀胱がんに対する手術の代わりに膀胱化学療法を検討する (CALIBER)
CALIBER - 低リスクの非筋層浸潤性膀胱がんにおける化学切除と外科的管理に関する第 II 相無作為化実現可能性研究
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.
Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.
調査の概要
詳細な説明
CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.
Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.
Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.
Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.
All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.
Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
London、イギリス、NW1 2BU
- University College Hospital
-
Manchester、イギリス、M23 9LT
- Wythenshawe Hospital
-
Manchester、イギリス、M20 2LR
- Withington Hospital
-
-
Cheshire
-
Macclesfield、Cheshire、イギリス、SK10 3BL
- Macclesfield District General Hospital
-
-
Cleveland
-
Middlesbrough、Cleveland、イギリス、TS4 3BW
- James Cook University Hospital
-
-
Cumbria
-
Whitehaven、Cumbria、イギリス、CA28 8JG
- West Cumberland Hospital
-
-
Devon
-
Exeter、Devon、イギリス、EX2 5DW
- Royal Devon and Exeter Hospital
-
Plymouth、Devon、イギリス、PL6 8DH
- Derriford Hospital
-
-
Dorset
-
Bournemouth、Dorset、イギリス、BH7 7DW
- Royal Bournemouth Hospital
-
Dorchester、Dorset、イギリス、DT1 2JY
- Dorset County Hospital
-
-
England
-
Carlisle、England、イギリス、CA2 7HY
- Cumberland Infirmary
-
-
Essex
-
Chelmsford、Essex、イギリス、CM1 5ET
- Broomfield Hospital
-
Harlow、Essex、イギリス、CM20 1QX
- Princess Alexandra Hospital
-
-
Gloucestershire
-
Cheltenham、Gloucestershire、イギリス、GL53 7AN
- Cheltenham General Hospital
-
Gloucester、Gloucestershire、イギリス、GL1 3NN
- Gloucestershire Royal Hospital
-
-
Greater Manchester
-
Manchester、Greater Manchester、イギリス、OL1 2JH
- Royal Oldham Hospital
-
-
Hampshire
-
Basingstoke、Hampshire、イギリス、RG24 9NA
- Basingstoke and North Hampshire Hospital
-
Southampton、Hampshire、イギリス、SO16 6YD
- Southampton General Hospital
-
-
Herefordshire
-
Hereford、Herefordshire、イギリス、HR1 2ER
- Hereford County Hospital
-
-
Kent
-
Dartford、Kent、イギリス、DA2 8DA
- Darent Valley Hospital
-
Gillingham、Kent、イギリス、ME7 5NY
- Medway Maritime Hospital
-
-
Lancashire
-
Preston、Lancashire、イギリス、PR2 9HT
- Royal Preston Hospital
-
-
Leicestershire
-
Leicester、Leicestershire、イギリス、LE5 4PW
- Leicester General Hospital
-
-
Middlesex
-
Harrow、Middlesex、イギリス、HA1 3UJ
- Northwick Park Hospital
-
-
Oxfordshire
-
Headington、Oxfordshire、イギリス、OX3 7LE
- Churchill Hospital
-
-
South Yorkshire
-
Sheffield、South Yorkshire、イギリス、S10 2JF
- Royal Hallamshire Hospital
-
-
Suffolk
-
Ipswich、Suffolk、イギリス、IP4 5PD
- Ipswich Hospital
-
-
Surrey
-
Croydon、Surrey、イギリス、CR7 7YE
- Croydon University Hospital
-
Guildford、Surrey、イギリス、GU2 7XX
- Royal Surrey County Hospital
-
-
Tyne and Wear
-
Newcastle upon Tyne、Tyne and Wear、イギリス、NE7 7DN
- Freeman Hospital
-
-
West Midlands
-
Wolverhampton、West Midlands、イギリス、WV10 0QP
- New Cross Hospital
-
-
West Sussex
-
Chichester、West Sussex、イギリス、PO19 6SE
- St Richard's Hospital
-
Worthing、West Sussex、イギリス、BN11 2DH
- Worthing Hospital
-
-
West Yorkshire
-
Wakefield、West Yorkshire、イギリス、WF1 4DG
- Pinderfields General Hospital
-
-
Worcestershire
-
Kidderminster、Worcestershire、イギリス、DY11 6RJ
- Kidderminster Hospital
-
Redditch、Worcestershire、イギリス、B98 7UB
- Alexandra Hospital
-
Worcester、Worcestershire、イギリス、WR5 1DD
- Worcester Royal Hospital
-
-
Yorkshire
-
Leeds、Yorkshire、イギリス、LS9 7TF
- St James's University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Written informed consent
- NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
- Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
- Aged 16 or over
- Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
- Negative pregnancy test for women of child-bearing potential
Exclusion Criteria:
- Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
- Any history of histologically confirmed non-TCC bladder cancer
- Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
- Any prior treatment of the trial entry recurrence (including biopsy)
- Previous MMC chemotherapy other than a single instillation at diagnostic surgery
- Known allergy to MMC
- Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
- Known or suspected reduced bladder capacity (<100ml)
- Significant bleeding disorder
- Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
- Active or intractable urinary tract infection
- Urethral stricture or anything impeding the insertion of a catheter
- Large narrow neck diverticula
- Significant urinary incontinence
- Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
- Unable or unwilling to comply with study procedures or follow up schedule
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Chemoresection
4 once weekly outpatient intravesical instillations 40mg Mitomycin C |
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
他の名前:
|
|
他の:Surgical Management
Surgical management according to local practice |
Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Complete response rate with chemoresection
時間枠:3 months
|
Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response. |
3 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment compliance in chemoresection group
時間枠:Duration of treatment (3 weeks)
|
Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant. |
Duration of treatment (3 weeks)
|
|
Salvage surgery rates
時間枠:3 years
|
Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups |
3 years
|
|
Progression-free survival
時間枠:3 years
|
Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause. |
3 years
|
|
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
時間枠:up to 12 months
|
Measuring side effects of both treatments using clinician reported toxicity scales |
up to 12 months
|
|
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
時間枠:up to 12 months
|
Assessing side effects and impact of both treatments on patient reported quality of life. |
up to 12 months
|
|
Health service utilisation
時間枠:up to 12 months
|
Assessed using prospective data collection of health resource usage. |
up to 12 months
|
|
Recurrence free interval
時間枠:up to 12 months
|
Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months |
up to 12 months
|
協力者と研究者
捜査官
- 主任研究者:Hugh Mostafid、Royal Surrey County Hospital NHS Foundation Trust
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- ICR-CTSU/2013/10041
- 2013-005095-18 (EudraCT番号)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。